Ritmole 300mg (Propafenone Hydrochloride)

Adult dose

The individual maintenance dose should be determined under cardiac monitoring, including electrocardiogram (ECG) monitoring and repeated blood pressure measurements. Adults: Administer propafenone hydrochloride orally at a dose of 450-600 mg per day (one 150 mg tablet 3 times daily or one 300 mg tablet 2 times daily). In some cases, the dose may be increased to 900 mg per day (one 300 mg tablet or two 150 mg tablets 3 times daily). This dosage regimen applies to patients weighing approximately 70 kg. For patients weighing less, the daily dose should be reduced according to body weight. The daily dose may be exceeded only in exceptional circumstances and under the strict supervision of a cardiologist. In particular, in elderly patients, patients with a history of myocardial damage, and patients with hepatic or renal impairment, initiate treatment at a low dose and increase cautiously while monitoring whether the blood concentration of the medicine is appropriate. The first dose increase should be made after at least 3-4 days. Patients with ventricular arrhythmias should undergo careful cardiac examination at the start of treatment. Treatment should be initiated in these patients only when emergency cardiac equipment is available and monitoring can be assured; regular examinations are required during treatment (for example, standard ECG at one-month intervals, Holter monitoring at 3-month intervals, and, if possible, exercise ECG). If ECG changes occur, such as QRS widening or QT prolongation greater than 25%, PR prolongation greater than 50%, QT prolongation greater than 500 ms, or an increase in the frequency or severity of arrhythmias, a decision should be made on whether to continue treatment. This medicine has a bitter taste and surface anesthetic effects; swallow it with a small amount of liquid after a meal. When prescribing this medicine, consider that there is no conclusive evidence that treatment with Class I antiarrhythmic agents helps prolong life.

This medication is used to control heart rhythms, but caution is necessary as it may increase the risk of death in patients with ventricular arrhythmias within 2 years following a myocardial infarction. Patients with severely weakened heart function, uncontrolled heart failure, certain cardiac conduction disorders, severe bradycardia, and those within 3 months post-myocardial infarction should not use this medication. Additionally, patients with Brugada syndrome, severe hypotension, severe electrolyte imbalances, and those with severe pulmonary diseases or myasthenia gravis should not be administered this medication. In patients with renal or liver dysfunction, mild cardiac conduction disorders, the elderly, and those with airway obstruction diseases such as asthma, this medication should be used cautiously as it may worsen symptoms. This medication can cause various side effects including decreased heart rate, cardiac conduction disturbances, heart failure worsening, dizziness, nausea, liver function abnormalities, neurological symptoms, skin rash, and more. If symptoms occur, immediate consultation with a physician is necessary. Regular electrocardiogram (ECG) tests are required to closely monitor the heart condition, and if abnormalities are observed, dosage adjustment or discontinuation may be necessary. This medication may interact with other drugs, so patients taking other medications must inform their doctor or pharmacist, as concurrent use with certain medications may increase the risk of cardiac side effects. During pregnancy, the use of this medication may affect the fetus, thus it should only be used when the benefits of treatment outweigh the risks. During breastfeeding, it is advisable to avoid administration or cease breastfeeding. The safety in children has not been established, thus it should be used cautiously in pediatric patients. Elderly patients may experience more side effects due to decreased liver and kidney function, so treatment should start at a low dose and the patient’s condition should be monitored frequently. In case of an overdose, serious symptoms such as heart rhythm abnormalities, hypotension, and seizures may occur, requiring immediate emergency treatment. This medication is restricted for use in patients with heart disease and should be taken only after careful monitoring of the patient’s condition.

Significant decrease in heart rate, conduction disorders, increase in heart rate, ventricular fibrillation, ventricular tachycardia, ventricular flutter, worsening heart failure, orthostatic hypotension, postural hypotension, nausea, loss of appetite, abdominal distension, vomiting, constipation, thirst, abdominal pain, bitter taste, numbness of the mouth, diarrhea, gastric pain, hepatocellular damage, cholestasis, jaundice, hepatitis, dizziness, headache, fainting, extrapyramidal symptoms, fatigue, dyskinesia, sensory abnormalities, anxiety, nightmares, sleep disorders, seizures, unease, confusion, agitation, leukopenia, neutropenia, thrombocytopenia, agranulocytosis, skin erythema, itching, hives, erythema, rash, hepatitis, allergic reactions, hypersensitivity reactions, anorexia nervosa, blurred vision, lupus syndrome, erectile dysfunction, fatigue, chest pain, elevated liver enzymes, warmth, flushing, malaise, myalgia, edema, elevated triglycerides, convulsions, bronchospasm, reduced sexual desire, decreased sperm count, emergence of Brugada syndrome symptoms or ECG abnormalities

Store this medication in a tightly sealed container to prevent air or moisture exposure. It is advisable to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help preserve the medication's efficacy for a longer period.

Appearance

White round film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle